Unlocking the Next Wave of Asia’s Global Biopharma Advancements

In 2026, BioCentury, BayHelix, and Insights Partner McKinsey & Company continue the debate about Asia's emerging Arc of Innovation – this time in Seoul, Korea. 

Why Korea?

Biotech's moment: From Alteogen to Ligachem to OliX and Orum, Korea biotechs are partnering with pharma and putting Korea innovation on the global map.

R&D, manufacturing: 20 years of government support has turned Korea into a global hub for clinical research and transformed Korea CDMOs like Samsung into partners of choice
for Western innovators.

NewCo ready?: Western VCs are sourcing biopharma innovation from Asia. Is Korea the next hotspot for assets and NewCo formation? 

What Will I Learn?

Highlights:

Globalizing Asian Innovation: The BioCentury Scene Setter asks whether routing Asia assets to the West can be sustained, and will it result in more Asia biotechs?

The NewCo Model: The Investor Roundtable asks whether Western and Asia investors see NewCos as the best path forward to globalizing Asia's innovation?

Pharma Licensing: The Dealmakers Showcase asks pharma BD&L leaders if the wave of licensing from Asia is here to stay.

Why Should I Attend?

The East-West Summit is the leading C-level conference connecting Asian and Western biopharma executives and investors — broaden your network, engage in strategic discussions and secure the right partnerships.

Network, partner and debate with:

• VCs and PEs
• Biopharma BD&L Leaders
• Biotech C-Suite
• Family Offices
• Financial Dealmakers

Meet key players from across Asia-Pacific, including:

• Australia
• China
• Japan
• India
• South Korea
• Singapore and Southeast Asia

Deliver Thought Leadership

Share your insights, elevate your brand and position yourself as a peer in BioCentury's network of biopharma decision-makers.

Learn More